Biotech company Biogen (NASDAQ:BIIB) reported Q1 CY2025 results , with sales up 6.1% year on year to $2.43 billion. Its ...

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to ...

Biogen Inc. (BIIB) came out with quarterly earnings of $3.02 per share, missing the Zacks Consensus Estimate of $3.26 per share. This compares to earnings of $3.67 per share a year ago.

Biogen Inc (NASDAQ:BIIB) reported a strong start to the year with a significant increase in revenue from new product launches, contributing to 45% of product revenue. The company received FDA Fast ...

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the June 13th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options ...

Wall Street analysts forecast that Biogen Inc. (BIIB) will report quarterly earnings of $3.32 per share in its upcoming release, pointing to a year-over-year decline of 9.5%. It is anticipated ...

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by Hsbc Global Res from a “strong-buy” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

Biogen (NASDAQ:BIIB – Free Report) had its price objective raised by Royal Bank of Canada from $221.00 to $225.00 in a research note issued to investors on Tuesday morning,Benzinga reports.

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...